Reminds Shareholders of May 26th Deadline for Submitting Proxies
TORONTO--(BUSINESS WIRE)--May. 22, 2009--
Biovail Corporation (NYSE/TSX:BVF) today reminded its shareholders to
use their BLUE proxy to vote for the Biovail nominees to the Board of
Directors and to reject the two nominees proposed by dissident
shareholder Eugene Melnyk.
As Biovail’s 2009 Annual and Special Meeting is quickly approaching, it
is extremely important that shareholders vote as soon as possible.
Biovail notes that at this time only proxies submitted by FAX or MAIL
can be counted because the dissident shareholder has taken steps to
prevent the use of electronic and telephone voting. The Company asks
that shareholders please submit voting instruction forms or BLUE proxies
by FAX or MAIL as soon as possible to ensure every vote can be counted
in time for the meeting.
To be effective, BLUE proxies must be received before and no later than
10:00 a.m. (Toronto time) May 26, 2009. Even if shareholders have
already voted using the dissident proxy, they have every right to change
their vote simply by executing and submitting the BLUE form of proxy; it
is the later-dated proxy that will be counted.
“We ask all our shareholders to remember that every vote is important in
determining the future course of their Company,” said Dr. Douglas
Squires, Chairman of the Biovail Board of Directors. “We remain
confident that we have the right Board and management team in place to
continue the successful implementation of our New Strategic Focus. We do
not believe the Melnyk nominees add to the Board’s expertise, experience
or ability to deliver value to our shareholders.”
Biovail reminds its shareholders that three leading independent proxy
advisory firms, RiskMetrics Group, Glass Lewis & Co., and PROXY
Governance, Inc., each recommend that Biovail shareholders vote using
the BLUE proxy FOR the Biovail nominees.
As previously announced, Biovail’s 2009 Annual and Special Meeting will
be held at 10:00 a.m. (Eastern time) on Thursday May 28, 2009 in the
Glenn Gould Studio of the CBC Canadian Broadcasting Centre, 250 Front
Street West, Toronto, Ontario.
The Proxy to Vote is BLUE
On behalf of all shareholders, Biovail is currently reviewing and
considering all available legal remedies arising from the termination of
electronic voting as a result of the form of proxy prepared by Mr.
Melnyk, which has made it significantly more difficult for non
registered shareholders to submit their vote. In the interim,
non-registered shareholders should vote the BLUE proxy by either fax or
mail, depending if the shareholder lives in Canada or the United States.
Shareholders should contact their broker or intermediary to ensure that
their voting instruction form is properly sent to Broadridge, the
independent company responsible for tabulating votes. Shareholders with
any questions about how to vote their shares should contact Biovail’s
proxy solicitation agent Georgeson: toll-free in North America at
1-866-676-3028 (Bank and broker and collect calls: 1-212-806-6859).
Biovail continues to urge all shareholders to vote their BLUE form of
proxy in favour of the election of Biovail's slate of director nominees
and in favour of the Biovail resolutions.
Caution Regarding Forward-Looking Information and "Safe Harbor"
Statement
To the extent any statements made in this release contain information
that is not historical, these statements are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and may be forward-looking information within the meaning
defined under applicable Canadian securities legislation (collectively,
"forward-looking statements"). These forward-looking statements relate
to, among other things, our objectives, goals, targets, strategies,
intentions, plans, beliefs, estimates and outlook, and can generally be
identified by the use of words such as "believe", "anticipate",
"expect", "intend", "plan", "will", "may", "target" and other similar
expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or circumstances
are forward-looking statements.
Although Biovail believes that the expectations reflected in such
forward-looking statements are reasonable, such statements involve risks
and uncertainties and readers are cautioned not to place undue reliance
on such statements. Certain material factors or assumptions are applied
in making forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements. Important
factors that could cause actual results to differ materially from these
expectations include, among other things, the risks detailed in our
Management Proxy Circular and from time to time in our filings with the
U.S. Securities and Exchange Commission and the Canadian Securities
Administrators, as well as our ability to anticipate and manage the
risks associated with the foregoing. Additional information about these
factors and about the material factors or assumptions underlying such
forward-looking statements may be found in the body of this news
release, as well as under the heading "Risk Factors" contained in Item
3.D of Biovail's most recent Annual Report on Form 20-F.
About Biovail Corporation
Biovail Corporation is a specialty pharmaceutical company engaged in the
formulation, clinical testing, registration, manufacture, and
commercialization of pharmaceutical products. The Company is focused on
the development and commercialization of medicines that address unmet
medical needs in niche specialty central nervous system (CNS) markets.
For more information about Biovail, visit the Company’s web site at www.biovail.com.
For further information, please contact Nelson F. Isabel at 905-286-3000
or send inquiries to ir@biovail.com.
Source: Biovail Corporation
Biovail Corporation
Nelson F. Isabel, 905-286-3000
Vice-President,
Investor Relations & Corporate Communications
